Skip to main content

Clinical trial XL184-311

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Organ Thyroïd
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Exelixis
EudraCT Identifier 2018-001771-21
Inclusion criteria RECIST 1.1
Last update